Found: 3
Select item for more details and to access through your institution.
Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
- Published in:
- BJU International, 2011, v. 107, n. 12, p. 1923, doi. 10.1111/j.1464-410X.2010.09726.x
- By:
- Publication type:
- Article
Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
- Published in:
- BJU International, 2010, v. 105, n. 8, p. 1082, doi. 10.1111/j.1464-410X.2009.08956.x
- By:
- Publication type:
- Article
Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
- Published in:
- BJU International, 2009, v. 104, n. 6, p. 800, doi. 10.1111/j.1464-410X.2009.08483.x
- By:
- Publication type:
- Article